ERCC1codon118单核苷酸多态性与非小细胞肺癌铂类化疗的临床预后研究

摘要

目的:探讨肿瘤石蜡组织中ERCC1 codon118单核苷酸多态性(single nucleotide polymorphism,SNP)与接受铂类药物化疗非小细胞肺癌(chemotherapy;non-small-cell lung cancer,NSCLC)患者临床预后之间的关系.方法:采用聚合酶链反应-限制性内切酶片段长度多态性(PCR-RFLP)的方法评价47例石蜡包埋NSCLC肿瘤组织中DNA修复基因ERCC1第118位密码子的单核苷酸多态性,并比较不同基因型与NSCLC组织临床病理及铂类化疗预后之间的关系.结果:所有NSCLC患者中位生存时间为16.0月 (95% CI,16.4-28.4月),中位无进展生存期为8.0月(95% CI,9.4-16.9月).ERCC1 codon118与NSCLC临床病理特征均未见相关性.携带ERCC1 C/C基因型的NSCLC患者的中位总生存时间为25.0月,而携带C/T及T/T基因型患者的中位总生存时间仅为10.5月,两者有统计学差异 (P=0.012).携带ERCC1 C/C基因型的NSCLC患者的中位无进展生存期为13.2月,而携带C/T及T/T基因型患者的中位无进展生存期仅为6.0月,两者有统计学差异 (P=0.029).结论:ERCC1 codon118基因单核苷酸多态性与接受铂类药物化疗的NSCLC患者的总生存时间和无进展生存期有关,在一定程度上可以作为判断NSCLC患者铂类药物化疗的预后指标.%Objective : ERCCI is emerging as essential elements in repairing platimun - DNA adducts. The aim of this study is to investigate whether the single nucleotide polymorphism ( SNP ) in Excision repair cross - complementation group 1( ERCC1 ) 118C→T is associated with the clinical prognosis of platinum - based chemotherapy in non small - cell lung cancer. Methods : SNP of ERCC1 118C→T was genotyped hy PCR - restrictive fragment length polymorphism( PCR - RFLP ). The pathological parameters and survival data were evaluated according to the different genotypes in 47 NSCLC patients. Results: ERCC1 118C→T was not related to clinic pathological parameters in NSCLC ( P ＞0. 05 ). The median survival of patients with C/C genotypes was 25. 0 months compared to 10. 5 months of C/T or T/T genotypes ( P = 0. 012 ). In Cox regresssion models , ERCC1 118C→T was significantly associated with overall survival time of NSCLC patients ( P =0. 015 ). Conclusion: ERCC1 codon118 SNP might be a predictive marker of survival for NSCLC patients receiving platinum - based chemotherapy.